Inhaled corticoids in asthmatic patients: effect on body mass index and spirometry
Monday, March 5, 2018
South Hall A2 (Convention Center)
Rosilane dos Reis Pacheco, MD, Mayra Coutinho Andrade, MD, Natalia falci Pedroso, Priscila Takejima, MD, Marcelo V. Aun, MD, Jorge Elias Kalil Filho, MD, PhD, Pedro Giavina-Bianchi, MD PhD FAAAAI, Rosana C. Agondi, MD, PhD
RATIONALE: The key treatment for persistent asthma is inhaled corticosteroid (IC). Severe asthmatic patients usually require high doses of IC for long periods of time. High doses of IC may lead to suppression of adrenal and other adverse effects, as obesity

METHODS: This was a retrospective study based in electronic medical records of adult asthmatic outpatients followed at a tertiary hospital. Asthmatic patients according to GINA were assessed for a period of six years. All of them were in IC treatment. Body mass index (BMI) and spirometry were assessed after a period of six years, as well as eventual change in IC dose during that period

RESULTS: Eighty-six patients were included in the study. The mean age was 58.1 years, and 81.4% of the patients were female. All of them initially, in 2010, used budesonide ≥ 800 mcg/day. After six years of follow-up, 20 patients (23.3%) decreased their IC dose to 600 mcg/day or under (mean dose of 390 mcg/day); 66 patients (76.6%) maintained or increased their IC dose (mean dose of 1152 mcg/ day). There was no change in BMI and FEV1 during this period. FEV1 changed from 71.7% of predicted value to 68.6% at the end of evaluation.

CONCLUSIONS: Patients with severe asthma require high doses of IC to control the disease. This study observed that patients who maintained a high dose of IC for a period of 6 years showed no change in BMI and only a slight reduction of FEV1 was observed in this period